Literature DB >> 33303554

Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease.

Scott Matson1, Joyce Lee2, Oliver Eickelberg3.   

Abstract

Rheumatoid arthritis associated interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF) are distinct diseases; however, they share several clinical, radiographic and genetic features. For instance, usual interstitial pneumonia (UIP), which is an ILD pattern required for a diagnosis of IPF, is also the most common ILD pattern in RA-ILD. The presence of UIP in RA-ILD is a poor prognostic sign with outcomes similar to those seen in IPF. The recent finding of a shared genetic susceptibility between IPF and RA-ILD has sparked additional interest in this relationship. This review outlines these similarities and differences in clinical presentation, appearance and outcomes in RA-ILD and IPF.In addition, this review highlights previous research in molecular biomarkers in both conditions, exploring areas of overlap and distinction. This focus on biomarkers in IPF and RA-ILD aims to highlight potential areas of discovery and clues to a potential shared pathobiology through investigation of novel molecular markers or the repurposing of biomarkers from one condition to the other.The drive to better understand RA-ILD by leveraging our knowledge of IPF is underscored by our divergent treatment paradigms for these conditions and the concern for potential harm. As a result of advancing our understanding of the links between IPF and RA-ILD, current strategies for diagnosis, screening and treatment of ILD may fundamentally change in the coming years. Until then, clinicians face difficult clinical questions regarding the co-management of the articular disease and the ILD in RA.
Copyright ©ERS 2021.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33303554     DOI: 10.1183/13993003.02533-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  Plasma IL-36α and IL-36γ as Potential Biomarkers in Interstitial Lung Disease Associated with Rheumatoid Arthritis: a Pilot Study in the Chinese Population.

Authors:  Weishuai Zheng; Xingxing Hu; Menglin Zou; Nie Hu; Weiwei Song; Rui Wang; Ying Liu; Qinhui Hou; Yuan Liu; Xiaoqi Chen; Zhenshun Cheng
Journal:  Inflammation       Date:  2022-08-31       Impact factor: 4.657

Review 2.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

3.  Dehydroevodiamine suppresses inflammatory responses in adjuvant-induced arthritis rats and human fibroblast-like synoviocytes.

Authors:  Yufang Dai; Jiaoe Sheng; Sanshan He; Qingchao Wu; Yunlong Wang; Linchong Su
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.